For transplant-ineligible patients with a broad range of characteristics, consider targeted immunotherapy with MONJUVI for treatment of R/R DLBCL in the second line1

Not an actual patient.
Profile in Practice #1:
Patient who progressed within 12 months*
and wants to stay local for treatment
Learn more from an expert
Play VideoTreatment History
- PR achieved after 4 cycles of R-CHOP; maintained through completion of first-line therapy1
- Disease progressed after a quick relapse—4 months following first-line therapy
Treatment Considerations
Disease severity2
- IPI: 3 (intermediate-high to high risk)
- Ann Arbor Stage: 3
Performance status/age2,3
- ECOG: 1
- Aged 65 years
Comorbidities
- Hypertension4
Patient considerations
- Eager to initiate treatment
-
Declined ASCT based on
- Lack of support system
- Preference to stay with current care team, but still seeking further treatment
This is a hypothetical patient profile.
R-CHOP=rituximab/
*Primary refractory patients were defined in L-MIND as those whose DLBCL relapsed or progressed after at least 3 months from completion of prior CD20-containing therapy.5
Treatment History
- First-line treatment: 6 cycles of R-CHOP1
- CR achieved following R-CHOP; progressed 6 months after completion of first-line therapy1
- Salvage chemotherapy failed to induce a response, ineligible for ASCT, and performance status declined to ECOG 2 following chemotherapy3
Treatment Considerations
Disease severity2,5
- IPI: 3 (intermediate-high to high risk)
- Ann Arbor Stage: 3
- Elevated LDH
- Bulky disease
Performance status/age2,3
- ECOG: 1
- Aged 68 years
Comorbidities
- Hypothyroidism
Patient considerations
- Lives in a rural area
- Wants to stay local and receive outpatient treatment
- Financial considerations are important
This is a hypothetical patient profile.
R-CHOP=rituximab/

Not an actual patient.
Profile in Practice #3:
Patient with R/R disease and comorbidities
Learn more from an expert
Play VideoTreatment History
- First-line treatment: 6 cycles of frontline R-mini-CHOP1
- Complete response achieved following R-mini-CHOP1
- Relapsed disease with symptoms 2 years after achieving CR
- Ineligible for ASCT due to comorbidities3
Treatment Considerations
Disease severity2
- IPI: 2 (low to low-intermediate risk)
- Ann Arbor Stage: 3
Performance status/age2,3
- ECOG: 2
- Aged 75 years
Comorbidities4
- Hypertension
- Atrial fibrillation (with pacemaker)
Patient considerations
- Looking for tumor reduction
This is a hypothetical patient profile.
R-CHOP=rituximab/